Gain new perspectives for faster progress directly to your inbox.
![cute little girl with white teddy bear](/sites/default/files/styles/insights_index_hero/public/images/INSGENENGWHP101675-Covalently-Linked-Inhibitors-Executive-Summary-Social-Article-1920x1080-Hero.jpg?h=d1cb525d&itok=-_6nOcID)
Historically, covalent inhibitors were avoided due to toxic side effects, but the latest breakthroughs in targeting have created a new landscape of opportunities. New breakthrough drugs like ibrutinib, sotorasib, and afatinib are reshaping the landscape of covalent inhibitors. For leaders of R&D, this idea in brief highlights key players, forces, and publication trends that enable better navigation of the opportunities ahead.